Amgen owes $20.2 million in antibody patent lawsuit, US jury says - Reuters

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOVk54b1g2SXZ6cFo2ejVzMlJ6N0tabXJFV1E4MXpfYVc0QjYtNGh6Q204WEZ5Wi0wTmkyVHc5SENJZG5XSkZUUks2eFJmbE44MEcyT0tfaHJWYU5fdk1tMUhPNGRrTWJFUnJiN0QwVWJMc1ZEeFZMSi03STVtaGJKMEt2RTFDSmJYZWY3blVzR0hTM3hpVF94UTFRTXZrRXNuV016d05GZTA2eGot?oc=5" target="_blank">Amgen owes $20.2 million in antibody patent lawsuit, US jury says</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

A Delaware federal jury found that Amgen Inc. and its Teneobio Inc. unit willfully infringed a mouse antibody patent held by Harbour Antibodies BV, awarding $20.2 million in damages—the full amount sought by Harbour.

A U.S. jury has determined that Amgen Inc. is liable for $20.2 million in damages for willfully infringing a mouse antibody patent asserted by Harbour Antibodies BV and others.

A U.S. jury has found Amgen Inc. liable for $20.2 million in damages for willfully infringing a mouse antibody patent held by Harbour Antibodies BV and others.